Though biologic medications have improved the treatment landscape by providing the solution to many unmet medical needs, biologics cost much more than small-molecule chemical medications. Biosimilars ...

Rectal adenocarcinoma, eosinophilic esophagitis, inflammatory bowel disease, diverticular perforation, and irritable bowel syndrome are among the gastrointestinal adverse events associated with the ...

The incidence of inflammatory bowel disease (IBD) has increased globally, 1 which has redirected the health care system’s focus toward safe and affordable pharmacologic interventions. As the patents ...

Nanoparticles enhance drug solubility, stability, and bioavailability, improving therapeutic outcomes for GI conditions like IBD through targeted delivery mechanisms. Hydrogel-based systems offer ...

The drug development process is driven by both medical need and business opportunity. The process itself is arduous, expensive and time-consuming. Invariably, it takes not only expertise, but robust ...